Devices descending from K191766
7 later devices reach VITEK 2 AST-Gram Negative Eravacycline (<=0.12 - >=4µg/mL) through their predicates, nearest generation first.
| Generation | Number | Device | Applicant | Decided | Own descendants | Recalls |
|---|---|---|---|---|---|---|
| +1 | K222430 | VITEK 2 AST-Gram Negative Fosfomycin (<=4 - >=256 µg/mL), VITEK 2 AST-GN Fosfomycin (<=4… | Biomerieux Sa, Inc. | 2023 | 0 | — |
| +1 | K213931 | VITEK 2 AST-Gram Negative Omadacycline (<=0.25 - >=16 µg/mL) | bioMerieux, Inc. | 2022 | 2 | — |
| +1 | K214023 | VITEK 2 AST-Gram Negative Ciprofloxacin (?0.06 - ?4 µg/mL) | bioMerieux, Inc. | 2022 | 0 | — |
| +1 | K201675 | VITEK 2 AST-Gram Negative Meropenem (<= 0.25 - >=16 µg/mL) | bioMerieux, Inc. | 2021 | 0 | — |
| +1 | K193299 | VITEK 2 AST-Gram Negative Ceftazidime (=<0.5 - =>32 µg/mL) | bioMerieux, Inc. | 2020 | 0 | — |
| +2 | K222073 | VITEK 2 AST-Gram Negative Cefazolin (<=1 - >=32 ug/mL) | bioMerieux, Inc. | 2023 | 1 | — |
| +3 | K251579 | VITEK 2 AST-Gram Negative Cefazolin (=<1-=>32 µg/mL) | bioMerieux, Inc. | 2025 | 0 | — |